Cardinal Health Delivers Double-Digit FY2026 Earnings Growth; Sets Strong FY2027 Outlook; Stock Up
Cardinal Health (CAH) reported Q4 FY2026 revenue of $63.7B, up 6% year over year. GAAP diluted EPS rose to $1.70 from $1.00, and non-GAAP diluted EPS to $2.91 from $2.08. FY2026 revenue increased to $254.2B, up 14%, with non-GAAP diluted EPS at $11.26. FY2027 non-GAAP EPS guidance is $12.40 to $12.60, and the board approved a $0.5158 quarterly dividend.
How this was made
The 30-second read
Why it matters
The combination of strong FY2026 earnings growth, a quantified FY2027 non-GAAP EPS outlook, and an additional $5B repurchase authorization provides a clear near-term catalyst for valuation and positioning.
Market read
Traders can update models and risk limits based on the new FY2027 EPS range and capital return plan, which can drive momentum in healthcare distribution names.
What to watch
Investors may scrutinize whether segment profit growth is sustainable and whether the FY2027 range leaves enough upside versus expectations, especially given the stock is already at a new 52-week high.
Background
Cardinal Health is a major US healthcare distributor with diversified segments including Pharmaceutical and Specialty Solutions, Medical Products and Distribution, and Nuclear and Precision Health/other offerings.
Ticker impact
Cardinal Health reported FY2026 results and guided FY2027 non-GAAP diluted EPS to $12.40 to $12.60, plus a new $5B buyback authorization.
Moderately positive, with follow-through possible if investors view FY2027 growth as credible across segments.
The article provides concrete FY2026 financials, a specific FY2027 EPS range, and incremental capital return authorization, which are direct inputs to valuation and positioning.
Market effects
Supports the view that healthcare distribution and specialty/pharma services are sustaining earnings momentum, potentially improving sentiment for peers with similar mix.
Primarily US-focused read-through to large-cap healthcare distributors and managed-care supply chains.
Limited direct global spillover, but tariff-refund and segment strength could influence broader supply-chain earnings expectations.
Counterpoint
Non-GAAP strength may be more sensitive to one-offs (tariff refunds) than GAAP, so the market could discount durability of the EPS trajectory.
Key entities
- companyCardinal Health
Reported Q4 and FY2026 results and issued FY2027 non-GAAP diluted EPS guidance, plus increased share repurchase authorization and a quarterly dividend.
